Some of Sanofi’s most high-profile readouts this year can’t have made for easy reading at the French pharma’s Paris ...

On the FDA’s docket for the back half of September is Merck’s proposed subcutaneous formulation of its blockbuster cancer ...

Sanofi to present new data from 14 abstracts across multiple sclerosis at ECTRIMS 2025 congress in Barcelona, Spain ...

Specialty and orphan drugs continue to dominate the development pipeline, and a new report from Optum Rx spotlights three products payers should be watching. | Specialty and orphan drugs continue to ...

While Sanofi originally had its eye on tolebrutinib when it purchased its partner Principia Biopharma for $3.7 billion five years ago, another one of the Bruton tyrosine kinase (BTK) inhibitors ...

The United Arab Emirates became the first country to approve tolebrutinib, clearing it to treat adults with nonrelapsing secondary progressive multiple sclerosis (SPMS). Sanofi’s oral BTK inhibitor is ...

ABU DHABI, 28 August (BelTA - Emirates News Agency) - In a landmark regulatory achievement that reflects the UAE’s leadership in accelerating access to innovative therapies, the Emirates Drug ...

In a landmark regulatory achievement that reflects the UAE’s leadership in accelerating access to innovative therapies, the Emirates Drug Establishment has announced the approval of “Tolebrutinib” as ...

The UAE has approved Tolebrutinib, the world’s first oral treatment for non-relapsing secondary progressive multiple sclerosis (SPMS). Developed to slow disability progression without relying on ...